Sosei Subsidiary Heptares Announces Strategic Drug Discovery Collaboration with Pfizer

Sosei Group Corporation

today announces that its wholly-owned subsidiary, Heptares Therapeutics has entered into a strategic drug discovery collaboration with Pfizer Inc.

to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas. Heptares will use its proprietary GPCR structure-guided platform to help deliver stabilised GPCRs (StaR® proteins), high-resolution crystal structures and other technologies to support the discovery of potential novel agents directed to the GPCR targets selected by Pfizer. Pfizer will be responsible for developing and commercialising any potential therapeutic agents (small molecules or biologics derived from StaR antigens) for each target and will have